[Fundamental and clinical study of T-1982 (cefbuperazone) in the field of obstetrics and gynecology].
Laboratory and clinical investigation of T-1982 (cefbuperazone) in the field of obstetrics and gynecology were carried out and the following results were obtained. The peak concentrations of 18.1-36.0 micrograms/ml were noted in pelvic cavity fluid at 1-3 hours after intravenous injection or drip infusion of 1 g of T-1982 in 3 cases after total hysterectomy for diffuse uterine cancer, then the concentrations decreased very slowly and were over 10 micrograms/ml at 6 hours after administration. Transfer rate of the drug into pelvic cavity fluid was 33-66% of the serum concentrations. In clinical trial, a total of 5 cases including 4 cases of external genital infections and 1 case of pelvic infection were treated with T-1982, and the results were evaluated as good in 3 cases, poor in 1 case and unknown in 1 case. Side effects were observed in 1 case who showed slight increase of GOT and GPT.
D000038:Abscess / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D002513:Cephamycins / Q000627:therapeutic use*; D005122:Exudates and Transudates / Q000032:analysis*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D010388:Pelvis; D010538:Peritonitis / Q000188:drug therapy; D014847:Vulvitis / Q000188:drug therapy
D002513:Cephamycins; C035978:cefbuperazone